| Phase 3 |
| NCT07333274 |
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible… |
Head & Neck Squamous Cell Carcinoma |
Recruiting |
| NCT04821778 |
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer |
Esophagus Cancer |
Recruiting |
| NCT04821843 |
Neoadjuvant Treatment Modalities in Esophageal Cancer |
Esophageal Cancer |
Recruiting |
| NCT07445048 |
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in… |
Head & Neck Squamous Cell Carcinoma |
Recruiting |
| NCT07524413 |
Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk… |
Nasopharyngeal Cancinoma (NPC) |
Not Yet Recruiting |
| NCT05652894 |
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With… |
Metastatic Colorectal Cancer |
Active, Not Recruiting |
| Phase 2/3 |
| NCT07535567 |
Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and… |
Head and Neck Squamous Cell Carcinoma |
Not Yet Recruiting |
| NCT07598318 |
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With… |
Cholangiocarcinoma |
Not Yet Recruiting |
| Phase 2 |
| NCT07353723 |
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar… |
Head & Neck Cancer |
Recruiting |
| NCT07457528 |
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally… |
Resectable Esophageal Squamous Cell Carcinoma |
Recruiting |
| NCT07464366 |
The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic… |
Salivary Gland Carcinomas |
Recruiting |
| NCT06959108 |
Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination… |
Locally Advanced Head and Neck Squamous Cell Carcinoma |
Recruiting |
| NCT07448142 |
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced… |
Colorectal Cancer (CRC) |
Recruiting |
| NCT07601737 |
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally… |
Head and Neck Squamous Cell Carcinoma |
Recruiting |
| NCT06770452 |
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced… |
Metastatic Pancreatic Carcinoma |
Recruiting |
| NCT07312578 |
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of… |
Esophageal Squamous Cell Carcinoma |
Enrolling by Invitation |
| NCT07353827 |
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for… |
Intrahepatic Cholangiocarcinoma (Icc) |
Not Yet Recruiting |
| NCT07354984 |
A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and… |
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
Not Yet Recruiting |
| NCT07394244 |
Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma |
Cutaneous Squamous Cell Carcinoma (CSCC) |
Not Yet Recruiting |
| NCT07518979 |
EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant… |
Penile Cancer |
Not Yet Recruiting |
| NCT07589049 |
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable… |
Head and Neck Squamous Cell Carcinoma |
Not Yet Recruiting |
| NCT07627321 |
Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for… |
NSCLC (Advanced Non-small Cell Lung Cancer) |
Not Yet Recruiting |
| Phase 1/2 |
| NCT07312422 |
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A… |
Pancreatic Cancer |
Recruiting |
| NCT06773130 |
HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic… |
Pancreatic Ductal Adenocarcinoma (PDAC) |
Active, Not Recruiting |
| Phase 1 |
| NCT07054307 |
MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or… |
Penile Cancer |
Recruiting |